Index removal puts Precigen stock in focus

Precigen (PGEN) has been removed from several Russell value and small cap benchmarks, an index reshuffle that can prompt passive funds to rebalance and temporarily change trading volumes or pricing.

For context, Precigen's share price has a 30 day share price return of 55.74% and a year to date share price return of 29.91%, while the 1 year total shareholder return of 192.63% and 3 year total shareholder return of about 4x suggest strong momentum that may now be meeting fresh volatility as index trackers respond to the Russell removals.

If you are reassessing your biotech exposure after Precigen's index reshuffle, it could be a useful moment to look at other healthcare focused AI opportunities using our screener for 40 healthcare AI stocks

Precigen now combines a gene and cell therapy pipeline, rapid revenue and net income growth, and a share price that has surged while being dropped from key Russell value indexes. How does that combination compare with today’s valuation?

Most Popular Narrative: 55.3% Undervalued

With Precigen last closing at $5.56 against a most followed fair value estimate of $12.45, the current price sits well below that narrative target.

Rapid uptake of PAPZIMEOS in a sizable and previously underserved adult RRP population, combined with strong physician enthusiasm and broad label coverage, supports a multi year ramp in product revenue as pent up demand converts into treated patients.

Analysts are factoring in steep revenue expansion, meaningfully higher margins and a richer future earnings multiple. It may be helpful to explore which assumptions are most important to this valuation story.

Result: Fair Value of $12.45 (UNDERVALUED)

However, the Precigen narrative still hinges on sustained PAPZIMEOS uptake in a single adult RRP indication, as well as on payer support that may not match current assumptions.

Another view on Precigen's valuation

While the analyst fair value of $12.45 suggests Precigen is 55.3% undervalued, the current P/B ratio of about 98x tells a very different story. This is particularly notable when the US Biotechs industry sits around 2.8x and peers average roughly 6x. That kind of gap can mean meaningful valuation risk if sentiment or expectations change.

Investors comparing these signals may want to weigh how much of Precigen's future potential is already reflected in the current share price and consider how comfortable they are with paying such a premium to book value in a company that is still loss making.

Next Steps

Given the mix of optimism and concern around Precigen's valuation signals, now is a good time to review the details yourself, weigh the upside and downside, and then check the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Precigen?

If you only stick with Precigen, you may miss other setups that fit your style. Use the Simply Wall St Screener to scan, compare, and pressure test fresh ideas.

• Jump on high potential opportunities early by scanning screener containing 19 high quality undiscovered gems that pair strong fundamentals with limited market attention.
• Strengthen the defensive side of your portfolio by reviewing 72 resilient stocks with low risk scores that score well on resilience and business quality.
• Target quality businesses trading below their estimated worth with the 44 high quality undervalued stocks, so you are not relying on a single stock story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.